Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q14108

UPID:
SCRB2_HUMAN

ALTERNATIVE NAMES:
85 kDa lysosomal membrane sialoglycoprotein; CD36 antigen-like 2; Lysosome membrane protein II; Scavenger receptor class B member 2

ALTERNATIVE UPACC:
Q14108; B4DKD8; E7EM68; Q53Y63

BACKGROUND:
The protein Lysosome membrane protein 2, with alternative names such as 85 kDa lysosomal membrane sialoglycoprotein and CD36 antigen-like 2, is integral to lysosomal function and viral defense. It specifically targets glucosylceramidase (GBA1) to lysosomes and acts as a receptor for enterovirus 71, highlighting its dual role in cellular metabolism and immune response.

THERAPEUTIC SIGNIFICANCE:
Implicated in the autosomal recessive form of Epilepsy, progressive myoclonic 4, Lysosome membrane protein 2's dysfunction is linked to severe neurological and sometimes renal complications. The exploration of this protein's functions and mechanisms offers a promising avenue for the development of novel therapeutic interventions for this debilitating condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.